Categories
Piramal Pharma Limited — Updates, 10-05-2026: General Updates
10-05-2026 · 10:26 pm
Piramal Pharma's US FDA inspection at its Sellersville facility led to a Form-483 with three observations. Inspectors recommended VAI classification, and no issues relate to data integrity, indicating a limited operational impact. The company is preparing its response.
No comments yet. Be the first to comment!